Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Immuno-Oncology and Metabolic Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for FATP2/SLC27A2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | FATP2/SLC27A2 Recombinant Protein High purity (>95%), Endotoxin Controlled. Sequence Verified. Suitable for enzymatic and binding assays. |
View FATP2 Products |
| Gene Delivery | FATP2/SLC27A2 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation. Essential for functional fatty acid uptake assays. |
View FATP2 Products |
| Benchmark Ab | Anti-FATP2/SLC27A2 Benchmark Antibody Recombinant positive control for flow cytometry, IHC, and neutralization validation. |
View FATP2 Products |
| Validator | FATP2/SLC27A2 siRNA Set For target knockdown verification and specificity profiling. |
View FATP2 Products |
| Related Target A | SLC27A4 (FATP4) Close family homolog. Critical for off-target counter-screening to prevent systemic toxicity. |
View SLC27A4 Products |
| Related Target B | CD36 Co-transporter in lipid uptake pathways. Synergistic target in tumor microenvironment immunosuppression studies. |
View CD36 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational Integrity in Cell Assays | Lentivirus-driven stable overexpression ensures native multi-pass transmembrane folding for functional uptake assays. |
| Subfamily Cross-Reactivity (FATP1-6) | Sequence-verified homolog panels (SLC27A4, etc.) allow rigorous selectivity counter-screening. |
| Lack of Controls | Sequence-derived recombinant benchmark antibodies included for assay standardization. |
| False Positives in Small Molecule Screens | Validated siRNA sets included for target-specific knockdown rescue experiments. |
Live FATP2/SLC27A2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for FATP2/SLC27A2 therapeutics is intensifying, with major players shifting focus from traditional metabolic indications to cancer immunotherapy. FATP2 has emerged as a master regulator of lipid accumulation in polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs), driving resistance to immune checkpoint inhibitors. As first-generation small-molecule inhibitors enter preclinical and early clinical validation, the next wave of R&D is targeting FATP2-mediated ferroptosis pathways and combination regimens with anti-PD-1/PD-L1 therapies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | Academic Institutions, Biotech Startups | Solid Tumors, NASH/NAFLD | High-throughput BODIPY-fatty acid uptake assays using Lentivirus-overexpressing stable cell lines. |
| Monoclonal Antibodies | Biopharma Innovators | Metastatic Cancer, Immunotherapy Resistance | High-purity extracellular domain (ECD) recombinant proteins for binding affinity (SPR/ELISA) validation. |
| RNA Therapeutics / siRNA | RNAi Specialists | Hepatic Steatosis, Renal Diseases | Sequence-verified siRNA sets for in vitro knockdown correlation and target validation. |